MP-1 Biofeedback: Pattern Stimulus Versus Audio-feedback in AMD

Status Completed

Clinical Trial Summary

Background:

Biofeedback techniques have demonstrated their uselfulness in the treatment of maculopathies. We wanted to evaluate the efficacy of visual rehabilitation by means of two different types of biofeedback techniques in patients with age related macular degeneration (AMD).

Methods:

30 patients bilaterally affected by AMD were enrolled with a mean age of 76,38±8,77 yrs. Patients were randomly divided in two groups: Group A was treated with an acoustic biofeedback, Group B with luminous biofeedback of a black and white checkerboard flickering during the examination. All patients underwent a complete ophthalmological examination. Rehabilitation consisted in 12 training sessions of 10 minutes for each eye performed once a week for both groups. Statistical analysis was performed using t- test. P values less than 0.05 were considered statistically significant.

Results:

Group A: visual acuity at the end of rehabilitation had improved, but this result was not statistically significant (p=0.054), reading speed showed a significant statistical improvement (p=0.031), as well as the fixation stability (p=0.0023) and single point mean retinal sensitivity value (p=0.044).

Group B: visual acuity improvement at the end of rehabilitation was statistically significant (p=0.048), reading speed showed a statistically significant improvement (p=0.024), as well as fixation stability (p=0.0012) and mean single point retinal sensitivity value (p=0.027). Final results for both groups were compared and patients in group B showed results which were statistically more significant.

Conclusion:

A contrast rich flickering biofeedback stimulus showed a statistically significant improvement in training the patients to modify their preferred retinal locus (PRL) in comparison to acoustic biofeedback. It is possible that increased involvement of the various retinal cell populations with visual stimuli create more efficient ganglion cell response that better utilize the residual retinal function.

Clinical Trial Description

n/a

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01243645
Study type	Interventional
Source	University of Roma La Sapienza
Contact
Status	Completed
Phase	N/A

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03963817` - Snapshot Camera for AMD
Recruiting	`NCT04929756` - Eye Movement Rehabilitation in Low Vision Patients
Completed	`NCT04779398` - Association of MPOD Values With Blue Light.
Terminated	`NCT03275753` - Visual Function Tests in Age-related Macular Degeneration
Recruiting	`NCT03609307` - Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial	Phase 2/Phase 3
Completed	`NCT02909985` - Visual Activity Evoked by Infrared in Humans After Dark Adaptation	N/A
Completed	`NCT02556723` - Intravitreal Injections of Ziv-aflibercept for Macular Diseases	N/A
Active, not recruiting	`NCT01943396` - Treatment of AMD With Rheohemapheresis /RHF/	Phase 4
Completed	`NCT00963339` - Age-Related Macular Degeneration (AMD) - Usability Study	N/A
Completed	`NCT00376701` - Combination Therapy for Age-Related Macular Degeneration.	Phase 2
Completed	`NCT00800995` - Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)	Phase 3
Terminated	`NCT00347165` - Intravitreal Bevacizumab for Age-Related Macular Degeneration	Phase 2
Completed	`NCT04689789` - OCTA and Retinal Angiomatous Proliferation
Completed	`NCT02567604` - Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
Completed	`NCT02173496` - Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Recruiting	`NCT01991730` - Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients	N/A
Active, not recruiting	`NCT01657669` - Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results	Phase 4
Completed	`NCT00776763` - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab	Phase 2
Completed	`NCT00791570` - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy	Phase 1
Completed	`NCT00413829` - Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.